Hester Biosciences In Talks With Bharat Biotech For Production Of Covaxin Via Tech Transfer

New Delhi : Hester Biosciences on Sunday said it has tied up with the Gujarat government to explore production of COVID-19 vaccine through technology transfer from Bharat Biotech.

The Ahmedabad-based firm said it has already initiated the discussions with Bharat Biotech in this regard.

“A triparty consortium has been formed with the Government of Gujarat as the lead partner, to explore the prospects of manufacturing the Covid vaccine through technology from Bharat Biotech,” Hester Biosciences CEO and MD Rajiv Gandhi said in a statement.

The discussions are currently ongoing with Bharat Biotech towards reviewing the infrastructure at Hester, the technology adaption process and the regulatory compliances, he added.

Based on the outcome of the review, the next course of action will be determined, Gandhi noted.

Hester Biosciences is a leading player in the animal healthcare segment. It is the second largest poultry vaccine manufacturer in the country.

Only three vaccines have so far been approved to be sold in India — Covaxin, Covishield and Sputnik V.

Sputnik V has been approved to be imported from Russia by Dr Reddy’s, but is yet to be widely available in the country.

Last week the Delhi government urged the Centre to use its special power to allow more firms to manufacture vaccines.

Delhi Chief Minister Arvind Kejriwal wrote to Prime Minister Narendra Modi, saying the Centre should share the vaccine formula of the two manufacturers with other capable pharmaceutical companies to scale up production in the country.

He said the Centre can also terminate the monopoly on vaccine production through the patent law.

  • Related Posts

    Fujifilm India launches therapeutic endoscopy portfolio at Endocon 2026

    Fujifilm India, a leading healthcare technology company, has expanded its ELUXEO 8000 endoscopy portfolio with the launch of its next-generation therapeutic gastroscopes at Endocon 2026. India is witnessing a growing…

    Draft bill proposes powers for DIs to inspect online pharmacy office premises

    Amidst years of uncertainty over the regulation of e-pharmacies in the country, the draft Drugs, Medical Devices and Cosmetics Bill, 2026, proposes to bestow the powers with the drugs inspectors…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Fujifilm India launches therapeutic endoscopy portfolio at Endocon 2026

    Fujifilm India launches therapeutic endoscopy portfolio at Endocon 2026

    Draft bill proposes powers for DIs to inspect online pharmacy office premises

    Draft bill proposes powers for DIs to inspect online pharmacy office premises

    Argentina committed to reducing barriers to facilitate entry of Indian pharma sector: Government

    Argentina committed to reducing barriers to facilitate entry of Indian pharma sector: Government

    FDA cancels drug sale licences of Cipla Pharma & Life Sciences’ Pune Carry and Forwarding unit

    FDA cancels drug sale licences of Cipla Pharma & Life Sciences’ Pune Carry and Forwarding unit

    Delhi DCA mandates digital tracking for controlled substances on new DMS portal

    Delhi DCA mandates digital tracking for controlled substances on new DMS portal

    How much of Healthcare Research reaches Bedside in India? Or gets Lost in Translation?

    How much of Healthcare Research reaches Bedside in India? Or gets Lost in Translation?